PUBLICATION

Emergence of a Potent AChE Inhibitor with Antioxidant and Neuroprotection Abilities

Authors
Osama, A., Ji, M., Fang, J., Zhao, H., Zhang, B.
ID
ZDB-PUB-260114-6
Date
2025
Source
ACS Medicinal Chemistry Letters   17: 137143137-143 (Other)
Registered Authors
Keywords
Alzheimer’s disease, acetylcholinesterase, antioxidant, neuroprotection
MeSH Terms
none
PubMed
41531953 Full text @ ACS Med. Chem. Lett.
Abstract
Oxidative damage and cholinergic dysfunction are common pathological features of Alzheimer's disease (AD). Maintaining the redox balance of neurons and cholinergic signaling through antioxidants and acetylcholinesterase (AChE) inhibition may provide therapeutic benefits for AD. In this regard, we discovered three AChE inhibitors with more potency than the positive control (rivastigmine; IC50 = 24.5 μM). Among these active compounds, C5 (a flavonoid derivative) was the most potent AChE inhibitor with an IC50 of 5.02 μM, followed by C1, C6, and C2 with IC50 values of 7.94 μM, 8.13 μM, and 27.52 μM, respectively. Compound C5 also demonstrated strong neuroprotective activity, rescuing PC12 cells from H2O2-induced damage and scavenging various ROS models. Interestingly, C5 also prevented memory impairments in the scopolamine-induced cognitive dysfunction zebrafish model. Our findings suggest that C5 is a potential drug lead for cholinergic dysfunction-related disorders such as AD.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping